We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Bio-Rad Laboratories Class A
BIO
$8.91B
| $780K | 0.09% |
+2,177
| New | +$840K |
|
302
Ulta Beauty
ULTA
$23.4B
| $776K | 0.09% |
+1,943
| New | +$849K |
|
303
Teradata
TDC
$3.24B
| $774K | 0.09% |
+17,191
| New | +$841K |
|
304
DigitalOcean
DOCN
$15.1B
| $762K | 0.09% |
+31,701
| New | +$1.12M |
|
305
Zillow
Z
$8.3B
| $761K | 0.09% |
+16,482
| New | +$847K |
|
306
Sterling Infrastructure
STRL
$16.6B
| $745K | 0.09% |
+10,133
| New | +$709K |
|
|
AL
307
DELISTED
Air Lease Corp
AL
| $744K | 0.09% |
18,889
+5,775
| +44% | +$237K |
|
|
EXE
308
Expand Energy Corp
EXE
$21.5B
| $735K | 0.09% |
8,522
+1,408
| +20% | +$119K |
|
309
CRISPR Therapeutics
CRSP
$5.23B
| $734K | 0.09% |
+16,179
| New | +$836K |
|
310
California Resources
CRC
$4.66B
| $723K | 0.08% |
12,910
+8,143
| +171% | +$434K |
|
311
Atlassian
TEAM
$28B
| $721K | 0.08% |
3,577
+1,391
| +64% | +$264K |
|
312
Snap-on
SNA
$21.6B
| $719K | 0.08% |
2,818
+1,758
| +166% | +$475K |
|
313
HUB Group
HUBG
$2.92B
| $717K | 0.08% |
18,266
+11,426
| +167% | +$469K |
|
314
United Parcel Service
UPS
$92.7B
| $715K | 0.08% |
+4,589
| New | +$792K |
|
315
Transocean
RIG
$5.78B
| $715K | 0.08% |
87,049
-24,208
| -22% | -$198K |
|
|
MAXN
316
DELISTED
Maxeon Solar Technologies
MAXN
| $711K | 0.08% |
614
+218
| +55% | +$414K |
|
317
Netflix
NFLX
$306B
| $711K | 0.08% |
+18,830
| New | +$798K |
|
318
ManpowerGroup
MAN
$2.55B
| $710K | 0.08% |
+9,687
| New | +$754K |
|
319
Calix
CALX
$2.49B
| $706K | 0.08% |
+15,402
| New | +$697K |
|
320
ACM Research
ACMR
$5.7B
| $705K | 0.08% |
+38,939
| New | +$579K |
|
321
Lemonade
LMND
$4.18B
| $704K | 0.08% |
+60,574
| New | +$972K |
|
322
ASE Group
ASX
$85.1B
| $701K | 0.08% |
+93,176
| New | +$724K |
|
323
Southern Copper
SCCO
$163B
| $699K | 0.08% |
10,021
-3,650
| -27% | -$267K |
|
324
RPM International
RPM
$14.7B
| $698K | 0.08% |
+7,359
| New | +$717K |
|
325
Boise Cascade
BCC
$3.04B
| $689K | 0.08% |
6,685
+1,821
| +37% | +$187K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.